Medicare can pay for obesity drugs like Wegovy in certain heart patients
Time:2024-05-21 12:22:15 Source:opinionsViews(143)
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
You may also like
- Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
- Weaving Bright Future for Chinese, African Women
- Entrepreneur Helps Rural Women Shake off Poverty in Northwest China
- Young Chinese Devoted to Protecting Agricultural Heritages
- Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
- Zhang Guimei: Helping Impoverished Girls Improve Education, Changing Their Fates
- Tujia Woman Promotes Ethnic Culture Through Literature, Songs
- Repairer Breathes New Life into Damaged Ancient Books
- What a blast to work at NASA. Space agency is sky